Trials / Active Not Recruiting
Active Not RecruitingNCT05470595
A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
A Phase II, Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (estimated)
- Sponsor
- Technische Universität Dresden · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II clinical trial evaluates the efficacy, safety and tolerability of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be followed by maintenance with atezolizumab monotherapy until progression. |
Timeline
- Start date
- 2022-01-18
- Primary completion
- 2028-01-31
- Completion
- 2029-01-31
- First posted
- 2022-07-22
- Last updated
- 2026-04-15
Locations
15 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT05470595. Inclusion in this directory is not an endorsement.